Thank you Shailaja for posting this question!
Dear Glen,
Thanks for your response, may I ask a follow-up question, if the sponsor's DIBD was in Mar. 2, 2021 and their US SMP was received on Nov.2, 2021, they missed the initial harmonization date for submission DSUR (submit in Mar.2022), can they keep the reporting date of SMP and submit DSUR#1 covering Nov.2, 2021-Nov.1 2022? I mean if they don't request to harmonize the DIBD, is it ok to use US SMP date as data lock point? or they need to submit IND annual report instead to avoid this DIBD harmonize issue? Thanks!
------------------------------
Ziqi Zhang
Regulatory Project Manager
Raleigh NC
United States
------------------------------
Original Message:
Sent: 26-Oct-2020 09:14
From: Glen Park
Subject: Difference between DIBD and DSUR Data lock point
Anonymous has provided the correct information but I can add some additional nuance. If the DIBD is based on a clinical trial application approval outside the US, once an IND is open it is possible to synchronize the due date for the IND Annual Report and the DSUR date. A request can be submitted to FDA review division to change the IND AR date as long as there is not more than a year gap between the due date of the AR and the DSUR.
------------------------------
Glen Park PharmD
Executive Director, Regulatory Affairs and Quality Assurance
New York NY
United States
Original Message:
Sent: 26-Oct-2020 03:04
From: Anonymous Member
Subject: Difference between DIBD and DSUR Data lock point
This message was posted by a user wishing to remain anonymous
The DIBD is the initial/first date on which the investigational product becomes approved (ie, authorized for conduct in a clinical study) in any country. The following year, as well as annually thereafter, DLP is the date used to lock the database for the purpose of assessing the safety and efficacy data of the product up to that point.
For example, if a company receives a 'Study May Proceed' letter from the FDA for its investigational drug on Jan 3, 2020, DLP would be designated as Jan 2, 2021. On DLP, the company locks the database and prepares the various sections of the DSUR. The reporting period of the DSUR would be Jan 3, 2020 to Jan 2, 2021. Submission would be due 60 days later. The following year, DLP would be Jan 2, 2022 (reporting period Jan 3, 2021 - Jan 2, 2022) and so on.
Note: If an authorization was granted in a different country other than the US on an earlier date than Jan 3, 2020, then that date should be the DIBD.
Original Message:
Sent: 25-Oct-2020 21:05
From: Shailaja Kunda
Subject: Difference between DIBD and DSUR Data lock point
Hello RAPS members,
I have a question concerning definitions described in the FDA's E2F Developmental Safety Update Report. How does a company define a Developmental International Birth Date, and how does that differ from Data Lock Point during IND maintenance?
Thank you,
Shai
------------------------------
Shailaja Kunda
Research Professional | Regulatory Affairs | Quality Assurance | Project Management
Life Science & Healthcare
Denver CO
United States
------------------------------